Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.

Trial Profile

Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloid leukaemia; Myeloproliferative disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BUFLU
  • Most Recent Events

    • 07 Mar 2016 Results (n = 133) published in the Bone Marrow Transplantation.
    • 18 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top